UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Correction: Targeting DORIS Remission and LLDAS in SLE: A Review

Rheumatology and therapy., 2024-08, Vol.11 (4), p.1059-1061

2024

Volltextzugriff (PDF)

Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet. Rheumatology, 2024-08, Vol.6 (8), p.e537-e545

2024

Volltextzugriff (PDF)

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials

Annals of the rheumatic diseases, 2024-08, Vol.83 (8), p.1018-1027

2024

Volltextzugriff (PDF)

A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale

Clinical and experimental rheumatology, 2024-08, Vol.42 (8), p.1635

2024

Volltextzugriff (PDF)

The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis

Modern rheumatology, 2024-07, Vol.34 (4), p.720-731

2024

Volltextzugriff (PDF)

1502 Lupus low disease activity state attainment in the phase 3 placebo-controlled TULIP long-term extension trial of anifrolumab

Lupus science & medicine, 2024-05, Vol.11 (Suppl 2), p.A114-A115

2024

Volltextzugriff (PDF)

Characterization of the genetic determinants of context-specific DNA methylation in primary monocytes

Cell genomics, 2024-05, Vol.4 (5), p.100541-100541, Article 100541

2024

Volltextzugriff (PDF)

LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis

Lupus science & medicine, 2024-03, Vol.11 (Suppl 1), p.A169-A170

2024

Volltextzugriff (PDF)

Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohortsResearch in context

EBioMedicine, 2024-02, Vol.100, p.104946

2024

Volltextzugriff (PDF)

Targeting DORIS Remission and LLDAS in SLE: A Review

Rheumatology and therapy., 2023-12, Vol.10 (6), p.1459-1477

2023

Volltextzugriff (PDF)

Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce

Nature reviews. Rheumatology, 2023-09, Vol.19 (9), p.592-602

2023

Volltextzugriff (PDF)

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

Arthritis & rheumatology (Hoboken, N.J.), 2023-02, Vol.75 (2), p.253-265

2023

Volltextzugriff (PDF)

Single cell analysis of spondyloarthritis regulatory T cells identifies distinct synovial gene expression patterns and clonal fates

Communications biology, 2021-12, Vol.4 (1), p.1395-15, Article 1395

2021

Volltextzugriff (PDF)

The immunology underlying rheumatic diseases

The Biomedical & Life Sciences Collection, 2021-12, Vol.2021 (12), p.e1005153

Al-Mossawi, Hussein

2021

Volltextzugriff (PDF)

Ex vivo mass cytometry analysis reveals a profound myeloid proinflammatory signature in psoriatic arthritis synovial fluid

Annals of the rheumatic diseases, 2021-12, Vol.80 (12), p.1559-1567

2021

Volltextzugriff (PDF)

Nothing about us without us: involving patient collaborators for machine learning applications in rheumatology

Annals of the rheumatic diseases, 2021-12, Vol.80 (12), p.1505-1510

2021

Volltextzugriff (PDF)

Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the MONITOR-PsA study, a trials within cohorts study design

Trials, 2021-03, Vol.22 (1), p.185-185, Article 185

2021

Volltextzugriff (PDF)

Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis

Nature communications, 2020-09, Vol.11 (1), p.4767-4767, Article 4767

2020

Volltextzugriff (PDF)

Context-specific regulation of surface and soluble IL7R expression by an autoimmune risk allele

Nature communications, 2019-10, Vol.10 (1), p.4575-11, Article 4575

2019

Volltextzugriff (PDF)

Precision medicine in psoriatic arthritis: how should we select targeted therapies?

The Lancet. Rheumatology, 2019-09, Vol.1 (1), p.e66-e73

2019

Volltextzugriff (PDF)

Personalized medicine — a new reality in psoriatic arthritis?

Nature reviews. Rheumatology, 2018-08, Vol.14 (8), p.449-451

2018

Volltextzugriff (PDF)

Novel Therapeutic Targets in Axial Spondyloarthritis

Current treatment options in rheumatology, 2018, Vol.4 (2), p.174-182

2018

Volltextzugriff (PDF)

03.20Identification of chromatin modifying mechanisms in inflammatory macrophages in rheumatoid arthritis

Annals of the rheumatic diseases, 2017-03, Vol.76 (Suppl 1), p.A38-A38

2017

Volltextzugriff (PDF)

02.35Time of flight mass cytometry (cytof) and rna sequencing interrogation of 'pathogenic' gm-csf lymphocytes in human spondyloarthritis

Annals of the rheumatic diseases, 2017-03, Vol.76 (Suppl 1), p.A22-A23

2017

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(22)

Publikationsform

Sprache

Englisch
(34)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Correction: Targeting DORIS Remission and LLDAS in SLE: A Review

Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials

A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale

The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis

1502 Lupus low disease activity state attainment in the phase 3 placebo-controlled TULIP long-term extension trial of anifrolumab

Characterization of the genetic determinants of context-specific DNA methylation in primary monocytes

LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis

Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohortsResearch in context

Targeting DORIS Remission and LLDAS in SLE: A Review

Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis

Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

Single cell analysis of spondyloarthritis regulatory T cells identifies distinct synovial gene expression patterns and clonal fates

The immunology underlying rheumatic diseases

Ex vivo mass cytometry analysis reveals a profound myeloid proinflammatory signature in psoriatic arthritis synovial fluid

Nothing about us without us: involving patient collaborators for machine learning applications in rheumatology

Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the MONITOR-PsA study, a trials within cohorts study design

Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis

Context-specific regulation of surface and soluble IL7R expression by an autoimmune risk allele

Precision medicine in psoriatic arthritis: how should we select targeted therapies?

Personalized medicine — a new reality in psoriatic arthritis?

Novel Therapeutic Targets in Axial Spondyloarthritis

03.20Identification of chromatin modifying mechanisms in inflammatory macrophages in rheumatoid arthritis

02.35Time of flight mass cytometry (cytof) and rna sequencing interrogation of 'pathogenic' gm-csf lymphocytes in human spondyloarthritis

Aktive Filter

Suchergebnisse filtern